In contrast, when injected once daily, intermittent PTH amino acids 1‐34 (teriparatide) treatment boosts bone mass, increases bone formation, and reduces fractures in individuals with osteoporosis.5, 6, 7 Recently, the PTHrP analog abaloparatide has also been shown to boost bone mass and reduce fractures in patients with osteoporosis when given by once‐daily subcutaneous injection.8 Currently, teriparatide and abaloparatide represent the only FDA‐approved osteoporosis medications that stimulate new bone formation. The gene discussed is PTH; the disease is osteoporosis.